Gene therapy watch: 5-Year safety check for inherited blindness treatment
NCT ID NCT04312672
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 42 people who received a gene therapy for X-linked retinitis pigmentosa, an inherited eye disease that causes blindness. The goal was to check the treatment's safety over up to 5 years. Researchers also looked at whether patients' vision and ability to move around in low light improved.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Leeds Teaching Hospitals NHS Trust
Leeds, LS9 7TF, United Kingdom
-
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, 02114, United States
-
Moorfields Eye Hospital
London, EC1V 9EL, United Kingdom
-
Univ of Michigan Medical Center
Ann Arbor, Michigan, 48105, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene Therapy's lasting effects on vision tracked in Long-Term study
- Gene therapy offers hope for rare Blindness-Causing eye disease
- Gene therapy targets second eye in rare blindness disorder
- Gene therapy offers hope for rare blindness
- Experimental gene therapy aims to halt vision loss in rare eye disease
- Gene therapy shows promise for rare blindness disease